Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 7× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| QQQE | XBI | |
|---|---|---|
Market Cap | $1.45B | $10.11B |
Volume | 323,568 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $124.69 | $169.55 |
52-Week Low | $96.06 | $104.99 |
Typical Hold Time | 48 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.68, down 0.17% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators are neutral. The equal-weight strategy reduces technology concentration compared to the standard NASDAQ-100 ETF, offering diversified exposure to large-cap growth stocks. Recent news highlights tactical preference for QQQE over QQQ due to its fundamental and technical positioning.
The outlook for QQQE is positive, driven by its equal-weight approach mitigating single-stock risk and capturing broad Nasdaq growth. Key risks include market volatility and sector concentration shifts. Investment appeal lies in its structural diversification, though reliance on tech sector performance remains a factor for investors to weigh.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
